NEW YORK: The wrenching selloff in US high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed next week.
First-quarter earnings estimates have fallen sharply as many companies have blamed the brutal winter for weak outlooks.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
